Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. Bou Zgheib N, et al. Among authors: lancaster jm. Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26. Int J Oncol. 2012. PMID: 22552627 Free PMC article.
Molecular aspects of ovarian cancer.
Wenham RM, Lancaster JM, Berchuck A. Wenham RM, et al. Among authors: lancaster jm. Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):483-97. doi: 10.1053/beog.2002.0298. Best Pract Res Clin Obstet Gynaecol. 2002. PMID: 12413930 Review.
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.
Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Wenham RM, et al. Among authors: lancaster jm. J Soc Gynecol Investig. 2003 Sep;10(6):381-7. doi: 10.1016/s1071-5576(03)00141-2. J Soc Gynecol Investig. 2003. PMID: 12969782
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. Dressman HK, et al. Among authors: lancaster jm. J Clin Oncol. 2007 Feb 10;25(5):517-25. doi: 10.1200/JCO.2006.06.3743. J Clin Oncol. 2007. Retraction in: J Clin Oncol. 2012 Feb 20;30(6):678. doi: 10.1200/jco.2012.42.0331 PMID: 17290060 Retracted.
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Hsu DS, et al. J Clin Oncol. 2007 Oct 1;25(28):4350-7. doi: 10.1200/JCO.2007.11.0593. J Clin Oncol. 2007. Retraction in: J Clin Oncol. 2010 Dec 10;28(35):5229. doi: 10.1200/JCO.2010.33.7311 PMID: 17906199 Retracted.
133 results